Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small-cell lung cancer (NSCLC), the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. We conducted a phase II study of erlotini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: MORISE, MASAHIRO, TANIGUCHI, HIROYUKI, SAKA, HIDEO, SHINDOH, JOE, SUZUKI, RYUJIRO, KOJIMA, EIJI, HASE, TETSUNARI, ANDO, MASAHIKO, KONDO, MASASHI, SAITO, HIROSHI, HASEGAWA, YOSHINORI
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2014
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4179810/
https://ncbi.nlm.nih.gov/pubmed/25279187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.354
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados